Effect of chlorpheniramine and cimetidine, a histamine H1 and H2 antagonist on (3H)glucose uptake in the brain of adult rats lesioned with 5,7-dihydroxytryptamine as neonates

• Authors: Jadwiga Jośko , Jacek Drab , Przemysław Nowak , Ryszard Szkilnik , Dariusz Boroń , Marta Elwart , Janusz Konecki , Halina Brus , Ryszard Brus

Title variants

PL

Wpływ chlorfeniraminy i cymetydyny, antagonistów receptorów histaminowych H1 i H2 na wychwyt (3H)glukozy w mózgu dorosłych szczurów po podaniu noworodkom 5,7-dihydroksytryptaminy

• Languages of publication: EN

Abstracts

EN

BACKGROUND The aim of the study was to examine eff ect of chlorpheniramine (hista- mine H1 receptor antagonist) and cimetidine (histamine H2 receptor an- tagonist) on (3H)glucose uptake in the brain of adult rats lesioned with 5,7-dihydroxytryptamine (neurotoxin for the central serotoninergic sys- tem) as neonates. MATERIAL AND METHODS Male 3-days old Wistar rats were injected with serotoninergic neurons neurotoxin 5,7-dihydroxytryptamine, 75 μg icv. Control rats were injected with saline 10 μg icv. At 8 weeks level of 5-HT and 5-HIAA was estimat- ed in the striatum, frontal cortex and hippocampus of the brain. Other 8 weeks old animals of control and 5,7-DHT lesioned as neonates were injected with S(+)chlorpheniramine (H1 receptor antagonist) 10.0 mg/kg ip or with cimetidine (H2 receptor antagonist) 5.0 mg/kg ip. Control rats were injected with saline 1.0 ml/kg ip. 60 minutes later 6-(3H)-D-glucose was applied in a dose of 500 μCi/kg ip and 15 minutes later all rats were decapitated and their brains were excised, placed on the ice and sample of frontal cortex, striatum, hippocampus, thalamus with hypothalamus, pons and cerebellum were separated and weighted. Then in the examined tissues radioactivity was measured in liquid scintillation counter and ex- pressed in DPM/100 mg of wet tissue. RESULTS 5,7-DHT decreased signifi cantly the level of 5-HT and 5-HIAA in all examined tissues in the brain of adult rats. In rats neonatally lesioned with 5,7-DHT radioactivity signifi cantly increased as compare to the control. Chlorpheniramine prevent signifi cantly that eff ect in the frontal cortex and cimetidine in the frontal cortex, hippocampus and cerebellum. CONCLUSION From above we conclude that in the brain of mammalians the metabolic link between histaminergic and serotoninergic system exist in regulation of energetic prcesses connected with glucose metabolism.

PL

WSTĘP Celem pracy było zbadanie wpływu chlorfeniraminy, antagonisty receptora histaminowego H1 i cymetydyny, antagonisty receptora histaminowego H2 na wychwyt (3H)glukozy w mózgu dorosłych szczurów z lezją (zniszczenie) ośrodkowego układu serotoninergicznego wywołaną podaniem noworodkom neurotoksyny 5,7-dihydroksytryptaminy. MATERIAŁ I METODY Trzydniowe noworodki płci męskiej szczepu Wistar otrzymały do bocznej komory mózgu (icv) 75 μg 5,7-dihydroksytryptaminy (5,7-DHT), neurotoksynę układu serotoninergicznego. Zwierzęta kontrolne otrzymały icv 10 μl 0,9% roztworu NaCl. Po osiągnięciu 8 tygodni życia zwierzęta dekapitowano i w korze czołowej, prążkowiu oraz zakręcie hipokampa oznaczono zawartość 5-HT i 5-HIAA metodą HPLC/ED. Osobnej grupie badanej i kontrolnej podano S(+)chlorfeniraminę 10,0 mg/kg ip (antagonista receptora histaminowego H1) lub cymetydynę 5,0 mg/kg ip (antagonista receptora histaminowego H2). Zwierzęta kontrolne obu grup otrzymały 0,9% roztwór NaCl 1,0 ml/kg ip. Po 60 minutach wszystkie szczury otrzymały 6-(3H)-D-glukozę 500 μCi/kg ip. Po dalszych 15 minutach zwierzęta dekapitowano, wyjmowano z czaszki mózg, separowano z niego korę czołową, prążkowie, hipokamp, wzgórze z podwzgórzem, most i móżdżek, w których oznaczono radioaktywność przy użyciu licznika scyntylacyjnego. Wyniki wyrażono w DPM (Desintegrations Per Minute) na 100 mg świeżej tkanki. WYNIKI 5,7-DHT podany noworodkom znamiennie obniżył zawartość 5-HT i 5-HIAA w badanych fragmentach mózgu dorosłych szczurów. U zwierząt z lezją ośrodkowego układu serotoninergicznego we wszystkich badanych częściach mózgu wykazano znamienny wzrost wychwytu (3H)glukozy. Badani antagoniści receptorów histaminowych nie wpływali na wychwyt (3H)glukozy w mózgu zwierząt grupy kontrolnej, natomiast chlorfeniramina zapobiegała wychwytowi glukozy tylko w korze mózgowej, a cymetydyna w korze mózgowej, hipokampie i móżdżku zwierząt z lezją ośrodkowego układu serotoninergicznego wywołaną podaniem noworodkom 5,7-DHT. WNIOSKI Wyniki wskazują na metaboliczne powiązania w mózgu ssaków między układem serotoninergicznym i histaminergicznym.

Keywords

EN

5; 5-HIAA; 5-HT; 6-(3H)-D-glukoza; 6-3H-D-glucose; 7-DHT; brain; chlorfeniramina; chlorpheniramine; cimetidine; cymetydyna; mózg; rats; szczury

Discipline

• MEDICINE: MEDICINE

• Publisher: Śląski Uniwersytet Medyczny w Katowicach
• Journal: Annales Academiae Medicae Silesiensis
• Year: 2012
• Volume: 66
• Issue: 2
• Pages: 13–19

Contributors

author

Jadwiga Jośko

• Chair and Department of Medicine and Environmental Epidemiology School of Medicine with the Division of Dentistry in Zabrze Medical University of Silesia in Katowice ul. Jordana 19 41-808 Zabrze, Poland tel./fax [phone]

author

Jacek Drab

• Chair and Department of Medicine and Environmental Epidemiology

author

Przemysław Nowak

• Department of Pharmacology

author

Ryszard Szkilnik

• Department of Pharmacology

author

Dariusz Boroń

• Department of Histology and Embriology School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice

author

Marta Elwart

• Department of Pharmacology

author

Janusz Konecki

• Department of Histology and Embriology School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice

author

Halina Brus

• Department of Histology and Embriology School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice

author

Ryszard Brus

• Department of Pharmacology, High School of Strategic Planning in Dąbrowa Górnicza

References

• 1. Kostrzewa R.M. Mechanism of action of 6-hydroxydopamine, a dopaminergic neurotoxin. [In:] Mechanisms of degeneration and protection of the dopaminergic system. Segura-Aguilar J, ed. FP Graham Publishing Co. Johnson City TN 2001; 89–104.
• 2. Kwieciński A., Nowak P. Eff ect of prenatal manganese intoxication on (3H)glucose uptake in the brain of rats lesioned as neonates with 6-hydroxydopamine. Pharmacol. Rep. 2009; 61: 558-563.
• 3. Kostrzewa R.M., Gong L., Brus R. Serotonin (5-HT) system mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol. Exp. 1992; 53: 31–41.
• 4. Brus R., Kostrzewa R.M., Perry K.W., Fuller R.W. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine- lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J. Pharmacol. Exper. Ther. 1994; 260: 231–237.
• 5. Nowak P., Noras Ł., Jochem J., Korossy E., Drab J., Szkilnik R., Brus R. Histaminergic activity in rodent model of Parkinson’s disease. Neurotox. Res. 2009; 15: 246–251.
• 6. Nowak P., Drab J., Szkilnik R. i wsp.Thi- operamide eff ect on (3H)glucose uptake in the brain of adult rats neonatally lesioned with 5,7-dihydroxytryptamine. The Eigh- teenth Days of Neuropsychopharmacol- ogy. Ustroń-Jaszowiec, Poland. Pharmacol. Rep. 2009; 61: 375.
• 7. Magnusson O., Nilsson L.B., Westerland D. Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography – electrochemical detection system. J. Chromatogr. 1980; 221: 237–247.
• 8. Tabatabie T., Dryhust G. Molecular mechanisms of action of 5,6- and 5,7-dihydroxytryptamine [In:] Highly Selective Neurotoxins. Basic and Clinical Application Kostrzewa R.M., ed. Humana Press. Tatowa, New Yersey 2001: 269–291.
• 9. Brus R., Plech A., Kostrzewa R.M. Enhanced quinpirole response in rats lesioned neonatally with 5,7-dihydroxytryptamine. Pharmacol. Biochem. Behav. 1995; 50: 649–653.
• 10. Darves A.S., Gudelski G.A. Injection of 5-HT2 receptors induces glycogenolysis in the rat brain. Eur. J. Pharmacol. 2003; 464: 135–140.
• 11. Freo U., Riechieri G.L., Holloway H., Soncrant T.T. Time- and dose-dependent eff ects of the serotoninergic agent quipazine on ragional cerebral metabolism in rats. Brain Res. 1992; 600: 249–256.
• 12. Hommer D., Andreason P., Rio D. i wsp. Eff ect of m-chlorphenylpiperazine on regional brain glucose utilization: a positron emission subjects. J. Neurosci. 1997; 17: 2796–2806.
• 13. Panula P., Arratosinen M.D., Pilvoca U., Kostiloinen E. A histamine containing neuronal system in human brain. Neuroscience 1990; 29: 127–182.
• 14. Schwartz J.C., Arrang J.M., Garbarg M., Pollard H., Raut M.: Histaminergic transmission in the mammalian brain. Physiol. Rev. 1991; 71: 1–51.
• 15. Brown R.E., Stevans D.R., Haas H.L. The physiology of brain histamine. Progr. Neurobiol. 2001; 63: 637–672.
• 16. Goodchild R.E., Curt J.A., Hobson I. i wsp. Distribution of histamine H3-receptor bidning in the normal human basal ganglia: comparison with Huntington’s and Parkinson’s disease cases. Eur. J. Neurosci. 1999; 11: 449–456.
• 17. Ryn J.H., Yanai R., Sakurai E., Kim C.Y., Watanabe T. Ontogenic development of histamine receptor subtype demonstrated by quantitative autoradiography. Develop. Brain Res. 1995; 87: 101–110.
• 18. Arrang J.M., Goway M., Schwartz J.C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. 1983; 302: 812–817.
• 19. Arrang J.M., Gorbag M., Lancelot J.C. i wsp. Highly potent and selective ligands for histamine H3-receptors. Nature 1987; 327: 117–123.
• 20. Nishibori M., Itoh Y., Seaki K. Eff ect of microinjection of histamine into the brain on plasma levels of epinephrine and glucose in freely moving rats. Jap. J. Pharmacol. 1990; 54: 257–263.
• 21. Nonagaki K., Igucki A., Li X. i wsp. Role of brain – histamine H1 and H2 receptors in neostigmine-induced hyperglycemia in rats. Life Sci. 1972; 51: PL131–134.
• 22. Leckin A., Jarvikyla M., Tuomisto L. The eff ect of metaprine on glicoprivic feeding induced by 2-deoxy-D-glucose. Pharmacol. Biochem. Behav. 1994; 49: 853–857.
• 23. Molina P.E., Williams P., Abumrad R.N. Histaminergic contribution to the metabolic agent of neuroglucopenia. Am. J. Physiol. 1997; 272: R1918–R1924.
• 24. Brus R., Szkilnik R., Kostrzewa R.M. i wsp. Modulation of glucose uptake in rat brain after administration of quinpirole and SKF-38393, two central dopamine receptor agonists. Pharmacol. Comm. 1995; 7: 87–91.
• 25. Nowak P., Jochem J., Szkilnik R. i wsp. Histaminergic activity in adult rats neonatally lesioned with neurotoxins: DSP-4, 5,7-DHT and 6-OHDA (rodent model of Parkinson’s disease). The Eighteenth Days of Neuropsychopharmacology. Ustroń-Jaszowiec, Poland. Pharmacol. Rep. 2009; 61: 376.
• 26. Nowak P., Dąbrowska J., Bortel A. i wsp. Histamine H3 receptor agonist- and antagonist evoked vacous chewing movements in 6-OHDA-lesioned rats occurs in absence of change in microdialysate dopamine level. Eur. J. Pharmacol. 2006; 552: 46–54.

• Document Type: article